Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial-Reference-Cited by-同舟云学术

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Published:2013-09 Issue:10 Volume:14 Page:989-998
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Johnston Stephen RD,Kilburn Lucy S,Ellis Paul,Dodwell David,Cameron David,Hayward Larry,Im Young-Hyuck,Braybrooke Jeremy P,Brunt A Murray,Cheung Kwok-Leung,Jyothirmayi Rema,Robinson Anne,Wardley Andrew M,Wheatley Duncan,Howell Anthony,Coombes Gill,Sergenson Nicole,Sin Hui-Jung,Folkerd Elizabeth,Dowsett Mitch,Bliss Judith M

Funder

Cancer Research UK

Publisher

Elsevier BV

Subject

Oncology

Reference20 articles.

1. Endocrine therapy for advanced breast cancer;Johnston,2011

2. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial;Lonning;J Clin Oncol,2000

3. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer;Bertelli;Oncology,2005

4. Fulvestrant (faslodex) as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors—update of a phase II SAKK trial;Perey;Breast Cancer Res Treat,2004

5. Fulvestrant (‘Faslodex’) in pre-treated patients with advanced breast cancer: a single-centre experience;Steger;Eur J Cancer,2005

Cited by 250 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the median: Estimating survival times for patients starting endocrine therapy for estrogen receptor‐positive, metastatic breast cancer from recent randomized trials;Asia-Pacific Journal of Clinical Oncology;2024-06-16

2. Docetaxel-loaded nanoformulations delivery for breast cancer management: Challenges, recent advances, and future perspectives;Journal of Drug Delivery Science and Technology;2024-02

3. The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis;BMC Cancer;2024-01-02

4. The power of whole genomic sequencing in biomedical research and clinical applications;Comprehensive Precision Medicine;2024

5. Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy;Medical Oncology;2023-12-16